Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: The VISA observational study

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 2, 2007, Pages 180-184

  Cadranel, Jean François ^a   Boujenah, Jean Louis ^b   Bourlière, Marc ^c   Fontanges, Thierry ^d   Pol, Stanislas ^e   Trepo, Christian ^f   Ouzan, Denis ^g  

^a CENTRE HOSPITALIER LAENNEC   (France)

^b Hôpital Saint Joseph ^*

^c HÔPITAL SAINT JOSEPH   (France)

^d Centre Hospitalier Pierre Oudot   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f HÔTEL DIEU   (France)

^g INSTITUT ARNAULT TZANCK   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; QUESTIONNAIRE; SCORING SYSTEM; SELF INJECTION; SIDE EFFECT; SYRINGE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 33947181599     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)89352-3     Document Type: Article

References (11)

1. Roudot-Thoraval F. Modifications of epidemiological characteristics of hepatitis C. Gastroenterol Clin Biol 2002;26:B138-43.
2. Trinchet JC. Natural history of HCV infection. Gastroenterol Clin Biol 2002;26:B144-53.
3. Lucidarme D. Hepatitis C and drug use: epidemiology, screening, natural history and treatment. Gastroenterol Clin Biol 2002;26:B112-20.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
5. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002;36:S3-20.
6. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44.
7. Pariente A, Djilloul A, Cadranel JF. Treatment of chronic hepatitis C with interferon alpha and ribavirin. Results in "real life". Gastroenterol Clin Biol 2003;27:590-5.
8. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
9. Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005;39:S23-7.
10. Camma C, Licata A, Cabibbo G, Latteri F, Craxi A. Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother 2005;6:399-408.
11. Cournot M, Glibert A, Castel F, Druart F, Imani K, Lauwers-Cances V, et al. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004;28:533-9.